Drug Trial Radar · NCT05485753
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
Feb 10, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.
Conditions
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
Interventions
GNC-038Drug
Administration by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: Up to 17 days after the first dose
- Maximum tolerated dose (MTD) or maximum administrated dose (MAD)Time frame: Up to 17 days after the first dose
- Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 36 months
- The recommended dose for phase II clinical study(RP2D)Time frame: Up to 17 days after the first dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.